Search
BioVenture VoiCes Episode 44: BainCapital's Adam Koppel
Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take on where we are in the biotech cycle. Plus, the critical importance of mentors. Chapters Intro and early life - 1:13 UPenn - 8:10 McKinsey - 15:12 Joining Bain - 22:23 Public vs private equity - 27:53 Biogen - 37:47 Returning to Bain - 48:34 PIPEs - 56:02 Non-biotech veh
2 hours ago
From NYSE: Noetik has been building a large database from patient tumor samples to use AI to help understand which patients are more likely to respond to medicines in the future
CEO Ron Alfa describes the platform's design, and walks us through partnerships with Agenus and GSK.
3 days ago
From NYSE: HSBC Innovation Banking's Ryan Roller shares takeaways from an AI x Bio conference and offers thoughts on the state of the financing market
He says that computational biology companies still have an edge in fundraising today compared to more traditional areas. Note: HSBC Innovation Banking is a longtime sponsor of BiotechTV
3 days ago
From NYSE: Alloy Therapeutics, which has a service provider model of helping other companies develop therapies, recently crossed the $1B valuation mark on their series E and is now fully integrated
Founder & CEO Errik Anderson describes the company's capabilities today and highlights a recent detail to help Voro Therapeutics develop masked T-cell engagers as an example of Alloy's broad capabilities.
4 days ago
From NYSE: Anthropic called out Manifold Bio as a key feedback provider when they announced Claude for life sciences recently. CEO Gleb Kuznetsov explains, and updates us on the brain shuttle program
He describes why Manifold is focused on in vivo work, even to the extent that it is trying to develop a 'virtual organism'. Plus, an update on the brain shuttle program that is partnered with Roche (it is not a transferrin program), and he explains the Anthropic news.
4 days ago
From NYSE: Nabla Bio is using AI and its own dry and wet lab models to discover and develop new antibody and protein based therapeutics. One partner, Takeda, has already come back for more
Co-Founder and CEO Surge Biswas walks us through the platform and describes the type of work that Nabla is doing for partners. Currently, it already has struck deals with Bristol, Astra, and Takeda (twice).
4 days ago
.png){kind=logo}